首页> 美国卫生研究院文献>Springer Open Choice >Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine
【2h】

Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine

机译:带回家的纳洛酮用于阿片类药物过量的紧急临时管理:紧急药物的公共卫生应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Naloxone is a well-established essential medicine for the treatment of life-threatening heroin/opioid overdose in emergency medicine. Over two decades, the concept of ‘take-home naloxone’ has evolved, comprising pre-provision of an emergency supply to laypersons likely to witness an opioid overdose (e.g. peers and family members of people who use opioids as well as non-medical personnel), with the recommendation to administer the naloxone to the overdose victim as interim care while awaiting an ambulance. There is an urgent need for more widespread naloxone access considering the growing problem of opioid overdose deaths, accounting for more than 100,000 deaths worldwide annually. Rises in mortality are particularly sharp in North America, where the ongoing prescription opioid problem is now overlaid with a rapid growth in overdose deaths from heroin and illicit fentanyl. Using opioids alone is dangerous, and the mortality risk is clustered at certain times and contexts, including on prison release and discharge from hospital and residential care. The provision of take-home naloxone has required the introduction of new legislation and new naloxone products. These include pre-filled syringes and auto-injectors and, crucially, new concentrated nasal sprays (four formulations recently approved in different countries) with speed of onset comparable to intramuscular naloxone and relative bioavailability of approximately 40–50%. Choosing the right naloxone dose in the fentanyl era is a matter of ongoing debate, but the safety margin of the approved nasal sprays is superior to improvised nasal kits. New legislation in different countries permits over-the-counter sales or other prescription-free methods of provision. However, access remains uneven with take-home naloxone still not provided in many countries and communities, and with ongoing barriers contributing to implementation inertia. Take-home naloxone is an important component of the response to the global overdose problem, but greater commitment to implementation will be essential, alongside improved affordable products, if a greater impact is to be achieved.
机译:纳洛酮是一种公认​​的急救药物,用于治疗威胁生命的海洛因/阿片类药物过量。在过去的二十多年中,“带回家纳洛酮”的概念不断发展,包括为可能目睹阿片类药物过量的非专业人员(例如,使用阿片类药物的人的同伴和家庭成员以及非医疗人员)提供紧急物资),并建议在等待救护车时对服药过量的纳洛酮进行临时护理。考虑到阿片类药物过量死亡的问题日益严重,迫切需要更广泛的纳洛酮治疗途径,全世界每年有100,000多例死亡。在北美,死亡率的上升尤为明显,在该地区,由于海洛因和非法芬太尼的过量死亡导致的阿片类药物过量问题迅速增加,现在正在解决处方阿片类药物问题。仅使用阿片类药物是危险的,并且死亡风险会在特定的时间和背景下聚集在一起,包括监狱释放,医院和院所护理出院。提供带回家的纳洛酮需要引入新的立法和新的纳洛酮产品。这些包括预装注射器和自动注射器,以及至关重要的是,新的浓缩鼻喷雾剂(最近在不同国家批准了四种制剂)的起效速度可与肌内纳洛酮媲美,相对生物利用度约为40–50%。在芬太尼时代选择合适的纳洛酮剂量是一个不断争论的问题,但是批准的鼻喷雾剂的安全性要优于即兴使用的鼻药盒。不同国家/地区的新法规允许非处方销售或其他无处方的提供方式。但是,获取渠道仍然不平衡,许多国家和社区仍未提供带回家的纳洛酮,而且持续存在阻碍实施惰性的障碍。带回家的纳洛酮是应对全球用药过量问题的重要组成部分,但是,如果要获得更大的影响,则对实施的更大承诺将是必不可少的,同时还要改善负担得起的产品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号